"A flurry of new studies suggest that
several parts of the immune system can mount a sustained, potent response to
any coronavirus variant.
As people across the world grapple
with the prospect of living with the coronavirus for the foreseeable future,
one question looms large: How soon before they need yet another shot?
Not for many months, and perhaps not
for years, according to a flurry of new studies.
Three doses of a Covid vaccine — or even just two — are enough
to protect most people from serious illness and death for a long time, the
studies suggest.
“We’re starting to see now
diminishing returns on the number of additional doses,” said John Wherry,
director of the Institute for immunology at the University of Pennsylvania.
Although people over 65 or at high risk of illness may
benefit from a fourth vaccine dose, it may be unnecessary for most people, he
added.
Federal health officials including
Dr. Anthony S. Fauci, the Biden administration’s top Covid adviser, have also
said that they are unlikely to recommend a fourth
dose before the fall.
The Omicron variant can dodge antibodies — immune molecules
that prevent the virus from infecting cells — produced after two doses
of a Covid vaccine. But a third shot of the mRNA vaccines made by
Pfizer-BioNTech or by Moderna prompts the body to make a much wider variety of
antibodies, which would be difficult for any variant of the virus to evade,
according to the most recent study,
posted online on Tuesday.
The diverse repertoire of antibodies
produced should be able to protect people from new variants, even those that
differ significantly from the original version of the virus, the study
suggests.
“If people are exposed to another variant like
Omicron, they now got some extra ammunition to fight it,” said Dr. Julie
McElrath, an infectious disease physician and immunologist at Fred Hutchinson
Cancer Research Center in Seattle.
What’s more, other parts of the immune system can remember
and destroy the virus over many months if not years, according to at least four
studies published in top-tier journals over the past month.
Specialized immune cells called T cells produced after
immunization by four brands of Covid vaccine — Pfizer-BioNTech, Moderna,
Johnson & Johnson and Novavax — are about 80 percent as powerful against
Omicron as other variants, the research found. Given how different Omicron’s
mutations are from previous variants, it’s very likely that T cells would mount
a similarly robust attack on any future variant as well, researchers said.
This matches what scientists have found for the SARS
coronavirus, which killed nearly 800 people in a 2003 epidemic in Asia. In
people exposed to that virus, T cells have lasted more than 17 years. Evidence so
far indicates that the immune cells for the new coronavirus — sometimes called
memory cells — may also decline very slowly, experts said.
“Memory responses can last for
ages,” said Wendy Burgers, an immunologist at the University of Cape Town who
led one of the studies, published in
the journal Nature. “Potentially, the T-cell response is extremely long lived.”
Throughout the pandemic, a disproportionate amount of
research attention has gone to antibodies, the body’s first line of defense
against a virus. That’s partly because these molecules are relatively easy to
study: They can be measured from a drop of blood.
Analyzing immune cells, by contrast, requires milliliters of
blood, skill, specialized equipment — and a lot of time.
“It’s orders of magnitude slower and
more laborious,” Dr. Burgers said.
Few labs have the wherewithal to
study these cells, and their findings lag weeks behind those on antibodies.
Perhaps as a result, scientists have frequently overlooked the importance of
other parts of the immune system, experts said.
“Most people don’t even know what
they are — a lot of doctors and scientists are not completely clear what a T
cell is,” said Dr. Dan Barouch, a virologist at Beth Israel Deaconess Medical
Center in Boston who led one of the T-cell studies.
“Fundamentally, I would argue that T cells are
probably more important than what many people have given them credit for,” Dr.
Barouch said.
Antibodies spike after every shot of
vaccine — or after each exposure to the virus — and inevitably decline within a
few weeks to months.
Waning antibody levels after two
vaccine doses prompted federal officials to recommend boosters for everyone
older than 12. The extra shots fortified antibody levels and helped to contain
Omicron’s spread, but they too appear to lose some of their ability to prevent
infections within four months, according to recent data from the
Centers for Disease Control and Prevention.
Antibodies recognize two or three key parts of the spike
protein, a protrusion on the outside of the coronavirus that allows it to latch
on to human cells. But T cells detect many more parts of the spike, and so are
less likely to fail when the virus gains
mutations in some of them.
Vaccines also encode a memory of the
virus in B cells, which can churn out fresh batches of antibodies within four
or five days after a new exposure to the virus.
This dual punch of T and B cells
help explain why many people who received two or even three doses of vaccine
could still be infected with the Omicron variant, but only a small percentage
became seriously ill.
“You will see a decrease of the
antibody levels over time, but if memory B cells are still there, and memory T
cells are still there, they can kick back into action relatively quickly,” said
Alessandro Sette, an immunologist at the La Jolla Institute for Immunology who led a new study of T cells
published in Cell.
Memory B cells become increasingly
sophisticated over time, and they learn to recognize a diverse set of viral
genetic sequences. The longer they have to practice, the broader the range of
virus variants they can thwart.
Researchers showed last year that the
elite school inside of lymph nodes where the B cells train, called the germinal
center, remains active for at least 15 weeks after
the second dose of a Covid vaccine. In an updated study published in the journal Nature,
the same team showed that six months after vaccination, memory B cells continue
to mature, and the antibodies they produce keep gaining the ability to
recognize new variants.
“Those antibodies at six months are
better binders and more potent neutralizers than the ones that are produced one
month after immunization,” said Ali Ellebedy, an immunologist at Washington
University in St. Louis who led the study.
In the newest study, another team
showed that a third shot creates an even richer pool of B cells than the second
shot did, and the antibodies they produce recognize a broader range of
variants. In laboratory experiments, these antibodies were able to fend off the
Beta, Delta and Omicron variants. In fact, more than half of the antibodies
seen one month after a third dose were able to neutralize Omicron, even though
the vaccine was not designed for that variant, the study found.
“If you’ve had a third dose, you’re
going to have a rapid response that’s going to have quite a bit of specificity
for Omicron, which explains why people that have had a third dose do so much
better,” said Michel Nussenzweig, an immunologist at Rockefeller University who
led the study.
Memory cells produced after infection with the coronavirus,
rather than by the vaccines, seem less potent against the Omicron variant, according to a study published
last month in Nature Medicine. Immunity generated by infection “varies quite a
lot, while the vaccine response is much more consistently good,” said Marcus
Buggert, an immunologist at the Karolinska Institute in Sweden who led the
study.
Although most people, vaccinated or
not, show only a small drop in their T cell response against Omicron, about one
in five had “significant reductions of their responses” of about 60 percent,
Dr. Buggert said. The differences are most likely because of their underlying
genetic makeup, he said.
Still, the recent studies suggest
that in most people, the immunity gained from infection or vaccination will
hold up for a long while. Even if mutations in new variants change some of the
viral regions that T cells recognize, there would still be enough others to
maintain a reasonably strong immune response, experts said.
One big unknown is how slowly the T
cells may decline, and whether two doses of vaccine can create a long-lasting
response, or if instead people would need three — as some experts have
suggested — to cement immune memory.
“That’s a question that we don’t
know the answer to yet,” Dr. Burgers said. “Those are the kind of studies that
we’re going to need to do.”"
Komentarų nėra:
Rašyti komentarą